HER2-positive, Metastatic Breast Cancer
Conditions
Keywords
ARX788, HER2-positive breast cancer, Brain metastasis
Brief summary
A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is resistant or refractory to Tyrosine kinase inhibitors (TKI).
Detailed description
This is an open-label, single arm, phase 2 study of ARX788 in HER2-positive, metastatic breast cancer patients whose disease is resistant or refractory to TKI. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion. In this study, Simon's two-stage design is used. Subjects received treatment until disease progression, intolerable toxicity, withdrawal from the study, or discontinuation judged by the investigator. Drug efficacy and safety data will be collected.
Interventions
DRUGARX788
1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years, and ≤75 years, male or female; * Eastern Cooperative Oncology Group (ECOG) performance status of 0\ 2; * Breast cancer patients diagnosed as HR arbitrary/HER2-positive by pathological examination; * Metastatic breast cancer subjects previously treated with trastuzumab, taxane and EGFR-TKI-containing regimens; * MRI confirmed brain metastasis with at least one intracranial parenchymal untreated metastatic lesion; * Mannitol, bevacizumab, or hormone therapy is allowed before enrollment; * Adequate organ functions; * Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤1. * Patients who participate in the trial voluntarily, sign an informed consent, have good compliance and are willing to comply with the follow-up visit.
Exclusion criteria
* Pneumomeningeal metastases or cystic metastases confirmed by MRI or lumbar puncture; * Uncontrolled third space effusion; * Previous treatment with T-DM1 or other HER2-ADC drugs; * Received a whole-brain radiotherapy, chemotherapy, or surgery within 2 weeks prior to the first dose of ARX788, or trastuzumab-targeted therapy or endocrine therapy within 1 week, or palliative radiotherapy for bone metastases within 2 weeks; * Prior history of interstitial pulmonary disease requiring hormone therapy, drug-induced interstitial pulmonary disease, radiation pneumonia, or current clinically active interstitial pulmonary disease; * Suffering from keratitis, corneal diseases, retinal diseases or active eye infections that require intervention; * Unwilling or unable to stop wearing contact lenses for the duration of the study; * Participated in other clinical trials within 2 weeks prior to enrollment; * Receiving any antitumor therapy for any other tumor, bevacizumab for the control of brain edema and bisphosphonates for the treatment of bone metastases or the prevention of osteoporosis are the exception; * With a history of any malignancies other than breast cancer in the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin or squamous cell carcinoma of the skin; * Cardiac insufficiency; * Uncontrolled hypertension; * History of allergic reactions to any component of ARX788, or with a history of protein drug allergy, a history of specific allergies (asthma, rheumatism, eczematous dermatitis), or a history of other severe allergic reactions, who are unsuitable for ARX788 treatment as per the investigator's judgments; * Pregnancy or lactation; * History of immunodeficiency, including HIV-positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; * Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or syphilis; * History of neurological or psychiatric disorder, including epilepsy or dementia; * Suffering severe or uncontrolled systemic diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Central nervous system (CNS) clinical benefit rate (CBR) | 2 years | CNS CBR is defined as the percentage of subjects who have achieved complete response, partial response, and stable disease according to the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Site of first progression | 2 years | Record the organs where the disease first progressed during the study |
| Progression-free survival (PFS) | 2 years | PFS is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable subjects. Subjects will be censored at time of subsequent therapy |
| Overall survival (OS) | 2 years | Overall survival (OS) is defined as the time from first dose of study therapy to the date of death (any cause). Subjects who are alive will be censored at the last known time that the subject was alive |
| The number of subjects experiencing adverse events | 2 years | Patient safety and adverse events (AEs) will be evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. All AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability of the treatment. |
Countries
China
Contacts
Primary ContactTing Li
Outcome results
None listed